<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839991</url>
  </required_header>
  <id_info>
    <org_study_id>CBT307-1</org_study_id>
    <secondary_id>2019-004584-46</secondary_id>
    <nct_id>NCT04839991</nct_id>
  </id_info>
  <brief_title>Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.</brief_title>
  <acronym>POTENTIA</acronym>
  <official_title>A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients With PSMA+ Advanced and/or Metastatic Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crescendo Biologics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crescendo Biologics Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell&#xD;
      enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety&#xD;
      and torelability to determine MTD and RP2D.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FIH, Phase 1, open-label, multi centre, non randomised study of CB307, a trispecific&#xD;
      Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours.&#xD;
      The study will consist of a dose escalation and cohort expansion. Up to 50 patients will&#xD;
      participate. Patients will receive CB307 IV, until loss of clinical benefit, unacceptable&#xD;
      toxicity or end of study. The dose escalation may be adapted by the SRC based on clinical&#xD;
      experience and safety review.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">September 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Initial dose escalation cohorts followed by a single dose expansion cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label multi center non randomised study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>The nature and frequency of any DLTs during the DLT-monitoring period assessed based on NCI CTCAE v5.0. up to 18 months duration.</time_frame>
    <description>The objective of the study is to assess the safety and tolerability of the study drug CB307 and to determine the MTD (maximum tolerated dose)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate clinical efficacy measured as progression-free survival according to RECIST v.1.1 or PCWG3</measure>
    <time_frame>Progression-free survival according to RECIST v1.1 or PCWG3 up to 18 months duration; and change from baseline in anti-drug (CB307) antibodies (ADA up to 18 months duration</time_frame>
    <description>To measure how well the treatment succeeds in producing the desired effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure how the body processes CB307 in the body over time</measure>
    <time_frame>PK parameters of CB307: data collected at time point 0 at each dosing period. Up to 18 months duration.</time_frame>
    <description>To evaluate the pharmacokinetic trough levels before administration of CB307</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of CB307 T1/2</measure>
    <time_frame>Data collected up to 18 months duration.</time_frame>
    <description>To evaluate the pharmacokinetic T1/2 after 3rd dose via IV for multiple dose levels of CB307</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of CB307 Tmax</measure>
    <time_frame>Data collected up to 18 months duration.</time_frame>
    <description>To evaluate the pharmacokinetic Tmax after 3rd dose via IV for multiple dose levels of CB307</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure Tumour Immune response</measure>
    <time_frame>Tumor response per RECIST ver 1.1 up to 18 months duration</time_frame>
    <description>To determine the potential of CB307 to produce an immune response and assess the relationship with other outcome measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of CB307 to anti tumour response</measure>
    <time_frame>PSA response defined as a &gt;50% decrease in PSA up to 18 months duration</time_frame>
    <description>To evaluate the preliminary CB307 dose in relationship to activity of changes in tumour</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced and/or Metastatic Solid Tumours</condition>
  <arm_group>
    <arm_group_label>Multi center open label Dose Escalation followed by cohort expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB307</intervention_name>
    <description>Tri-specific Humabody targeting CD137, prostate specific membrane antigen and human serum albumin</description>
    <arm_group_label>Multi center open label Dose Escalation followed by cohort expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Capable of understanding the written informed consent.&#xD;
&#xD;
          2. Aged at least 18 years&#xD;
&#xD;
          3. Not amenable to standard of care.&#xD;
&#xD;
          4. ECOG PS 0-1&#xD;
&#xD;
          5. Has documented histologically confirmed diagnosis of PSMA+ advanced or metastatic&#xD;
             solid tumours&#xD;
&#xD;
          6. Has radiologically measurable disease per RECIST v1.1 or elevated serum PSA for&#xD;
             castration resistant prostate cancer patients with only bone metastasis&#xD;
&#xD;
          7. Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with autoimmune disease or regular immunosuppressants&#xD;
&#xD;
          2. Has discontinued from anti-CTLA 4, anti-PD1 or anti-PD-L1 antibody because of&#xD;
             intolerable toxicity&#xD;
&#xD;
          3. Has brain metastasis including leptomeningeal metastasis or primary brain tumour.&#xD;
&#xD;
          4. Has current or history of CNS disease&#xD;
&#xD;
          5. Has known active infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S Rajbally</last_name>
    <role>Study Director</role>
    <affiliation>Crescendo Biologics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MD</last_name>
    <phone>01223497140</phone>
    <email>Clinicaltrials@crescendobiologics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>S Rajbally</last_name>
    <phone>01223497140</phone>
    <email>SRajbally@crescendobiologics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <email>f.opdam@nki.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VUMC Research B.V</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <email>c.menke@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen,</name>
      <address>
        <city>Groningen</city>
        <zip>P.O. Box 30 001</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <email>e.g.e.de.vries@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <email>m.lolkema@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht Cancer Center</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <email>E.H.Gort-2@umcutrecht.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <email>fiona.thistlethwaite@christie.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Bebington</city>
        <state>Merseyside</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <email>isabel.syndikus@ccotrust.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <email>Johann.DeBono@icr.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <email>m.linch@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute, UK</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <email>tobias.arkenau@hcahealthcare.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Specific Membrane Antigen (PSMA)</keyword>
  <keyword>Solid Tumours</keyword>
  <keyword>Castration-resistant prostate cancer (CRPC)</keyword>
  <keyword>First in Human (FIH)</keyword>
  <keyword>Phase 1 Study</keyword>
  <keyword>CD137</keyword>
  <keyword>4-1BB</keyword>
  <keyword>Crescendo Biologics</keyword>
  <keyword>CB307</keyword>
  <keyword>Humabody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

